• Dosage of Tobramycin Sulfate APP in details
• Tobramycin Sulfate APP interactions
• Tobramycin Sulfate APP reviews

Dosage of Tobramycin Sulfate APP in details

Tobramycin Sulfate APP Dosage

Generic name: Tobramycin Sulfate APP 300mg in 5mL

Dosage form: inhalation solution

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Dosing Information

• Tobramycin Sulfate APP is a co-packaging of Tobramycin Sulfate APP inhalation solution ampules with a PARI LC PLUS Reusable Nebulizer. Administer as follows: One single-use ampule (300 mg /5 mL) of Tobramycin Sulfate APP inhalation solution twice a day by oral inhalation in alternating periods of 28 days on drug, followed by 28 days off drug.
• The 300 mg/5mL dose of Tobramycin Sulfate APP inhalation solution is the same for all patients regardless of age or weight.
• The doses should be taken as close to 12 hours apart as possible; they should not be taken less than 6 hours apart.

Administration of Tobramycin Sulfate APP Inhalation Solution

Each dose of Tobramycin Sulfate APP inhalation solution is administered by oral inhalation using only the co-packaged PARI LC PLUS Reusable Nebulizer (Model No. 022B81-T) included in the Tobramycin Sulfate APP, along with a DeVilbiss Pulmo-Aide air compressor (Model No. 5650D).

Tobramycin Sulfate APP inhalation solution is not for subcutaneous, intravenous or intrathecal administration.

Prior to administration, read the Patient Information/Instructions for Use for Tobramycin Sulfate APP for detailed information on how to use Tobramycin Sulfate APP and follow the manufacturer's instructions for use and care of the DeVilbiss Pulmo-Aide air compressor.

The entire Tobramycin Sulfate APP inhalation solution treatment should take approximately 15 minutes to complete. Continue treatment until all the Tobramycin Sulfate APP inhalation solution has been delivered, and there is no longer any mist being produced.

Tobramycin Sulfate APP inhalation solution should not be diluted or mixed with other drugs including dornase alfa (Pulmozyme®) in the nebulizer. Instruct patients on multiple therapies to take their medications prior to inhaling the Tobramycin Sulfate APP inhalation solution, or as directed by their physician.

Tobramycin Sulfate APP inhalation solution should not be used if it is cloudy, if there are particles in the solution, or if it has been stored at room temperature for more than 28 days.

More about Tobramycin Sulfate APP (Tobramycin Sulfate APP)

• Side Effects
• During Pregnancy or Breastfeeding
• Dosage Information
• Drug Interactions
• Support Group
• Pricing & Coupons
• 0 Reviews - Add your own review/rating
• Generic Availability

Consumer resources

• Tobramycin Sulfate APP (Advanced Reading)

• Other brands: Tobramycin Sulfate APP, Bethkis, Tobramycin Sulfate APP, Nebcin

Professional resources

• Tobramycin Sulfate APP (FDA)
• Tobramycin Sulfate APP Sulfate (AHFS Monograph)

Related treatment guides

• Cystic Fibrosis

What other drugs will affect Tobramycin Sulfate APP?

Before using Tobramycin Sulfate APP, tell your doctor if you are taking:

• furosemide (Lasix);
• ethacryinc acid (Edecrin); or
• mannitol (Osmitrol).

You may not be able to use Tobramycin Sulfate APP, or you may require a dosage adjustment or special monitoring during treatment if you are taking any of the medicines listed above.

Do not mix Tobramycin Sulfate APP with dornase alfa (Pulmozyme) in the nebulizer.

Drugs other than those listed here may also interact with Tobramycin Sulfate APP. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines, including herbal products.

Tobramycin Sulfate APP interactions

No clinical drug interaction studies have been performed with Tobramycin Sulfate APP. In clinical studies, patients receiving Tobramycin Sulfate APP continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. No clinical signs of drug interactions with these medicines were identified.

Concurrent and/or sequential use of Tobramycin Sulfate APP with other drugs with neurotoxic, nephrotoxic, or ototoxic potential should be avoided.

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. Tobramycin Sulfate APP should not be administered concomitantly with ethacrynic acid, furosemide, urea, or intravenous mannitol. The interaction between inhaled mannitol and Tobramycin Sulfate APP has not been evaluated.

References

1. DailyMed. "TOBRAMYCIN SULFATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
2. FDA/SPL Indexing Data. "VZ8RRZ51VK: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
3. MeSH. "Anti-Bacterial Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Tobramycin Sulfate APP are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Tobramycin Sulfate APP. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 19 here

Information checked by Dr. Sachin Kumar, MD Pharmacology